US 12384753
17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof
granted A61PA61P1/00
Quick answer
US patent 12384753 (17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof) held by Enanta Pharmaceuticals, Inc. expires Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Enanta Pharmaceuticals, Inc.
- Grant date
- Tue Aug 12 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 07 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61P, A61P1/00